PAMU
IOVA icon

Pictet Asset Management (UK)’s Iovance Biotherapeutics IOVA Stock Holding History

Pictet Asset Management (UK)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,100
Closed -$288K – 1805
2021
Q1 		$288K Hold
9,100
– – ﹤0.01% 1459
2020
Q4 		$422K Hold
9,100
– – ﹤0.01% 1223
2020
Q3 		$300K Buy
+9,100
New +$279K ﹤0.01% 1230

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Pictet Asset Management (UK)'s IOVA Position: Q2 2021 in Review

Pictet Asset Management (UK) sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 9,100 shares — an estimated $288K sold.

Pictet Asset Management (UK) first reported a position in IOVA in Q3 2020 and held it in 3 quarters. The position peaked at $422K in Q4 2020. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Pictet Asset Management (UK) reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Pictet Asset Management (UK) sold 9,100 Iovance Biotherapeutics shares in Q2 2021, an estimated $288K.
  • Pictet Asset Management (UK) first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 3 quarters.
  • Pictet Asset Management (UK)'s Iovance Biotherapeutics position peaked at $422K in Q4 2020.
  • 234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.